According to CoinMeta, Argenx SE ( NASDAQ : ARGX ) is preparing to demonstrate the efficacy of its drug Vyvgart in treating a wider range of autoimmune diseases. Baron Capital released its second-quarter 2026 investor letter, reporting that the fund grew by 11.99% this quarter, outperforming the 10.48% of the Russell 3000 Healthcare Index and the 15.44% of the Russell 3000 Index. Since its establishment, the fund has achieved an annualized growth of 10.61%. The fund is optimistic about healthcare, believing that improved biotechnology financing, strong acquisition activities, and the growth of an aging population will drive the industry forward.